Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 12

Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

November 4, 2024

James K. McCloskey, MD, John Theurer Cancer Center, Thomas W. LeBlanc, MD, MA

Panelists discuss how the treatment landscape for lower-risk MDS may evolve with emerging novel agents and combination strategies, including studies on luspatercept vs epoetin alfa, luspatercept combinations, elritercept, roxadustat, and canakinumab, potentially offering new options for patients with suboptimal responses to current therapies.

EP. 1: Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP. 2: Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP. 3: Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP. 4: Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP. 5: First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP. 6: Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP. 7: Second-Line LR- MDS Setting: Treatment Options and Considerations

EP. 8: Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP. 9: Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP. 10: First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP. 11: Imetelstat and IMerge Trial Review

Now Viewing

EP. 12: Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP. 13: The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

Are there any novel agents and/or combination strategies in LR-MDS that may change our treatment landscape for LR-MDS? (Potential suggestions below, feel free to comment on any additional studies.)

Luspatercept vs epoetin alfa NTD LR-MDS: ELEMENT-MDS trial.

Jonasova A, et al. Luspatercept plus erythropoietin in LR-MDS. EHA 2024, abstract P1886.

Komrokji RS, et al. Luspatercept plus ESA combinations in LR-MDS. Blood Adv. 2023.

Díez Campelo M, et al. Phase 2 study, elritercept (KER-050). EHA 2024, abstract S183.

Mittelman M, et al. Phase 3, roxadustat: Matterhorn Study. ASH 2023 abstract.

Sallman DA et al. Phase 1b/2 study evaluating canakinumab for 2L treatment in patients with LR-MDS. ASH 2023, abstract 620.